<< China Medical Technologies reports revenues of US$25.2 million for third-quarter fiscal 2009 | Royal Philips Electronics, Microsoft collaborate to improve Philips Healthcare's efficiency and productivity >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | हिन्दी | Русский | Svenska | Polski

SCLL signs agreement to provide research and assay services in support of Agennix's talactoferrin program

Published on March 3, 2010 at 4:35 AM · No Comments

Stem Cell Innovations (Pink Sheets: SCLL) announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.

"We are happy to enter into this contract with Agennix," said James H. Kelly, PhD, CEO of Stem Cell Innovations. "Our C3A cells provide a reliable and reproducible foundation on which to base the talactoferrin assays."

In addition to the talactoferrin assays, SCLL will provide other research and cell culture services to Agennix.

SOURCE Stem Cell Innovations, Inc.

360765d3-a40d-4f4c-911c-7b50a8fa2a67|0|.0

Posted in: Device / Technology News

Tags: Cancer, Cell, Lung Cancer, Non-Small Cell Lung Cancer, Sepsis, Small Cell Lung Cancer, Stem Cell, Toxicology

Related posts

AB SCIEX acquires mass spectrometry business of Labindia InstrumentsAB SCIEX, a global leader in life science analytical technologies, today announced that it has acqui...
Novel ways of killing TB causing bacteria discoveredResearchers at Albert Einstein College of Medicine of Yeshiva University have found two novel ways o...
Mice study shows obesity can increase risk of developing liver cancerObesity comes with plenty of health risks, but there's one that's perhaps not so well known: an incr...
Report on worldwide markets for lung cancer therapeuticsReportlinker.com announces that a new market research report is available in its catalogue: Lung Can...
StemCells’ novel neuroprotective approach for treating neurodegenerative diseasesStemCells, Inc. today announced the publication of preclinical data demonstrating for the first time...
The Gambia introduces pneumococcal immunisation programmeThe Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal v...
PET scans show if radiation is shrinking lung tumorsLung cancer patients may not need to wait till their radiation treatment is over to know if it worke...
Genmab starts HuMax-EGFr combination studyGenmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.